TP 5809
Alternative Names: TP-5809Latest Information Update: 28 Apr 2024
At a glance
- Originator Tolero Pharmaceuticals
- Developer Sumitomo Pharma; Sumitomo Pharma America
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hodgkin's disease
- No development reported Cancer